Date 13/12/2005 |
ARDANA ANNOUNCES ITS INTERIM RESULTS TO 30 SEPTEMBER 2005 |
| |
Date 09/11/2005 |
ARDANA SIGNS AGREEMENT WITH PHARMACURO TO MARKET STRIANT™SR IN THE NORDIC REGION |
Ardana announces
that it has signed an agreement under which Ardana grants Pharmacuro ApS exclusive rights to market Striant™SR, Ardana’s testosterone replacement therapy for male hypogonadism, in the Nordic region |
| |
Date 31/10/2005 |
ARDANA ANNOUNCES POSITIVE PHASE I RESULTS AND STARTS PHASE II TRIALS FOR NOVEL TESTOSTERONE CREAM |
Ardana announces positive results in a second Phase I study of its testosterone cream which is being developed as a treatment for testosterone deficiency in male hypogonadism.
|
| |
Date 05/10/2005 |
ARDANA ANNOUNCES GERMAN LAUNCH OF STRIANT™SR THROUGH CYTOCHEMIA AG |
Ardana announces that its partner, Cytochemia AG, has commenced marketing of Striant™SR, Ardana’s testosterone replacement therapy for male hypogonadism, in Germany. |
| |
Date 30/09/2005 |
MRC HUMAN REPRODUCTIVE SCIENCES UNIT SHORT-LISTED FOR THE TIMES HIGHER AWARD |
Professor Bob Millar, Director of the MRC Human Reproductive Sciences Unit (HRSU) in Edinburgh has been recognised for his work translating research into commercial products. He’s been short-listed in the Business Initiative of the Year category of The Times Higher Awards 2005. . |
| |
Date 21/09/2005 |
| ARDANA ACCELERATES ANTICIPATED LAUNCH OF TEVERELIX LONG ACTING (LA) IN BENIGN PROSTATIC HYPERPLASIA FOLLOWING PRE-IND MEETING WITH THE US FDA |
Ardana
today reports that the launch of its lead compound, the GnRH antagonist Teverelix Long Acting (LA) in benign prostatic hyperplasia (BPH), could be advanced by up to two years, following a pre-Investigational New Drug (IND) application meeting with the FDA at which consensus on the company’s development plan for the therapy was reached. It was previously expected that Teverelix in BPH could reach the market in 2012. |
| |
Date 07/09/2005 |
| CLINICAL DEVELOPMENT OF ARDANA'S TEVERELIX LONG ACTING (LA) IN PROSTATE CANCER CONTINUES ON TRACK FOLLOWING PRE-IND APPLICATION MEETING WITH THE US FOOD & DRUG ADMINISTRATION (FDA) |
Ardana
today announces that the company has had a pre-Investigational New Drug (IND) application meeting with the FDA to discuss the development for prostate cancer of its lead compound Teverelix LA, a GnRH antagonist.
|
| |
Date: 17/06/2005 |
| ARDANA
APPOINTS NEW NON-EXECUTIVE
TO THE BOARD |
Ardana today announces that Carol Ferguson has been appointed as a non-executive director and as Chair of the audit committee. |
| |
Date: 16/06/2005 |
| ARDANA
SIGNS AGREEMENT WITH CYTOCHEMIA TO MARKET STRIANT™ SR IN GERMANY |
Ardana announces that it has signed an agreement under which Ardana grants Cytochemia AG exclusive rights to market Striant™ SR in Germany. |
| |
Date: 26/05/2005 |
| ARDANA
ANNOUNCES SUCCESSFUL RESULTS IN A PHASE II STUDY OF TEVERELIX LA IN BENIGN PROSTATIC HYPERPLASIA |
Ardana plc (LSE:ARA) announces successful results from a Phase II study of the Gonadotrophin Releasing Hormone (GnRH) Antagonist, Teverelix LA (Long Acting) in patients with Benign Prostatic Hyperplasia (BPH). |
| |
Date: 12/05/2005 |
| ARDANA ANNOUNCES
SUCCESSFUL RESULTS IN SECOND PHASE II STUDY OF TEVERELIX LA IN PROSTATE CANCER |
| Ardana plc (LSE:ARA) announces successful results of a second Phase II study of the Gonadotrophin Releasing Antagonist (GnRH), Teverelix LA (Long Acting), in patients with advanced prostate cancer. |
| |
Date: 19/04/2005 |
| ARDANA ANNOUNCES POSITIVE RESULTS IN PHASE I STUDY OF ORAL GROWTH HORMONE SECRETAGOGUE |
| Ardana plc (LSE:ARA) today announces positive results in a Phase I study of its oral Growth Hormone Secretagogue (GHS), EP1572. |
| |
Date: 04/03/2005 |
| ARDANA ANNOUNCES THAT IT HAS COMPLETED ITS INITIAL PUBLIC OFFERING |
| Ardana today announces that it has successfully completed its Initial Public Offering. |
| |
Date: 17/02/2005 |
| ARDANA ANNOUNCES SUCCESSFUL RESULTS IN PHASE II TRIAL OF TEVERELIX IN PROSTATE CANCER |
| Ardana today announces successful results in a Phase II study of the Gonadotrophin Releasing Antagonist (GnRH), Teverelix LA (Long Acting), in patients with advanced prostate cancer. |
| |
Date: 03/02/2005 |
| ARDANA SIGNS THREE YEAR EXTENSION TO ITS EXCLUSIVE AGREEMENT WITH MRC HUMAN REPRODUCTIVE SCIENCES UNIT |
| Ardana has concluded a new agreement with the UK Medical Research Council (MRC) which gives Ardana exclusive rights to commercialise selected research areas in the MRC Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland. |
| |
